Individualized Weight Loss
*Based on Ivim’s published study, Ivim patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks when compared to another published clinical GLP-1 trial that included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks. Not a head-to-head study. RX required after clinical evaluation. This is a compounded medication and is not FDA-approved. Compounded drugs have not undergone FDA review for safety, efficacy, or quality. See Ivím website for full safety information. Results may vary.
Your Ivím GLP-1 ID Patient Journey
Here’s how it works:
What your individual program includes
Competitors
Medicine
ONLY
$850 value
coaching & community
$500 value
formulated supplements
Ivím Health App
What to Expect
Your Ivím GLP-1 ID Patient Journey
Understanding individualized compounded GLP-1 medications
Learn more about GLP-1s
-
Ivím Health Study Featured in Medscape: Are We Prescribing GLP-1s Wrong?
Ivím Health’s individualized GLP-1 care model was recently featured in Medscape in a clinical commentary examining standard prescribing practices for GLP-1 medications. The piece references Ivím Health’s published study of 1,131 patients, which showed 21.8% average total body weight loss over 68 weeks within […]
-
Dr. Jessica Duncan on GLP-1 Weight Regain: Why Stopping Medication Leads to Weight Return | KevinMD
Dr. Jessica Duncan, MD, DABOM, Medical Director at Ivím Health, recently published a clinical perspective on KevinMD examining why patients who stop GLP-1 therapy are at high risk for weight regain. In the piece, Dr. Duncan explains that obesity is a chronic, relapsing condition and […]
-
Two peer-reviewed studies published in Obesity Pillars report that Ivim Health patients receiving GLP-1 therapy within a comprehensive care protocol achieved up to 26.54% average weight loss in real-world observational cohorts.
COLUMBUS, Ohio, March 12, 2026 /PRNewswire/ — Millions of patients are on GLP-1 medications. New peer-reviewed research shows that comprehensive clinical support is a decisive factor in achieving superior outcomes. Two peer-reviewed studies published in Obesity Pillars demonstrate that patients receiving GLP-1 therapy within a […]
*Based on Ivim’s published study, Ivim patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks when compared to another published clinical GLP-1 trial that included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks. Not a head-to-head study. RX required after clinical evaluation. This is a compounded medication and is not FDA-approved. Compounded drugs have not undergone FDA review for safety, efficacy, or quality. See Ivím website for full safety information. Results may vary.
*Based on our internal data and individual patient outcomes may vary. This does not constitute a guarantee of specific results.
✝ These results include data from patients using both FDA-approved and compounded formulations.
Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes


